Technical Development of a New Meningococcal Conjugate Vaccine | Zendy

Carl E. Frasch | Zendy; Subhash V. Kapre | Zendy; CheHung Lee | Zendy; Jean-Marie Préaud | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Technical Development of a New Meningococcal Conjugate Vaccine

Author(s) -

Carl E. Frasch,

Subhash V. Kapre,

CheHung Lee,

Jean-Marie Préaud

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ595

Subject(s) - neisseria meningitidis , meningococcal vaccine , meningococcal meningitis , neisseriaceae , microbiology and biotechnology , conjugate vaccine , medicine , conjugate , bacterial meningitis , virology , meningitis , neisseria , pathogen , meningococcal disease , antibody , immunology , bacteria , immunization , antibiotics , biology , pediatrics , mathematical analysis , genetics , mathematics

Group A Neisseria meningitidis has been a major cause of bacterial meningitis in the sub-Saharan region of Africa in the meningitis belt. Neisseria meningitidis is an encapsulated pathogen, and antibodies against the capsular polysaccharide are protective. Polysaccharide-protein conjugate vaccines have proven to be highly effective against several different encapsulated bacterial pathogens. Purified polysaccharide vaccines have been used to control group A meningococcal (MenA) epidemics with minimal success.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research